{
    "clinical_study": {
        "@rank": "94223", 
        "arm_group": [
            {
                "arm_group_label": "opioid rotation", 
                "arm_group_type": "Experimental", 
                "description": "Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).\noral oxycodone : convert to oral hydromorphone or fentanyl patch\noral hydromorphone : convert to oral oxycodone or fentanyl patch\nfentanyl patch : convert to oral oxycodone or oral hydromorphone"
            }, 
            {
                "arm_group_label": "opioid dose escalation", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.\noral oxycodone : maintain oral oxycodone and titrate the dose\noral hydromorphone : maintain oral hydromorphone and titrate the dose\nfentanyl patch : maintain fentanyl patch and titrate the dose"
            }
        ], 
        "brief_summary": {
            "textblock": "Although opioid rotation is well known treatment modality in reducing pain and\n      opioid-induced neurotoxicity, it is not established whether opioid rotation is more\n      appropriate or opioid escalation is more effective in controlling significant  pain in\n      cancer patients under opioid medication.\n\n      - The purpose of this study is to determine effective therapy out of opioid rotation and\n      opioid dose escalation in patients with moderate to severe cancer pain who have been already\n      treated with strong opioid."
        }, 
        "brief_title": "Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Pain"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age > 18 years\n\n          -  patients who are being treated with one of strong opioids including oral oxycodone,\n             oral hydromorphone, or fentanyl patch with range from 60 mg to 200 mg of oral\n             morphine equivalent daily dose (MEDD)\n\n          -  moderate to severe cancer pain (numeric rating scale more than 3) at screening\n\n          -  patients without uncontrolled adverse effects associated with currently applied\n             opioid\n\n        Exclusion Criteria:\n\n          -  previous opioid rotation\n\n          -  unable to take oral medication\n\n          -  life expectancy less than a month\n\n          -  newly started chemotherapy and/or radiotherapy within past 2 weeks of screening\n\n          -  serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase >\n             2.5 times of upper normal limit\n\n          -  serum total bilirubin or creatinine > 1.5 times of upper normal limit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084355", 
            "org_study_id": "GNUH-2013-07-014"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "opioid rotation", 
                    "opioid dose escalation"
                ], 
                "intervention_name": "oral oxycodone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "opioid rotation", 
                    "opioid dose escalation"
                ], 
                "intervention_name": "oral hydromorphone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "opioid rotation", 
                    "opioid dose escalation"
                ], 
                "intervention_name": "fentanyl patch", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hydromorphone", 
                "Fentanyl", 
                "Oxycodone", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Significant cancer pain", 
            "at least numeric rating scale 4"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "email": "gose1@hanmail.net", 
                "last_name": "Se-Il Go, M.D.", 
                "phone": "+82 55 750 9454", 
                "phone_ext": "9454"
            }, 
            "facility": {
                "address": {
                    "city": "Jinju", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeongsangnam-do", 
                    "zip": "660-702"
                }, 
                "name": "Gyeongsang National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study", 
        "overall_contact": {
            "email": "gose1@hanmail.net", 
            "last_name": "Se-Il Go, M.D.", 
            "phone": "+82 55 750 9454", 
            "phone_ext": "9454"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The rate of successful pain control defined as a 30% or 2-point reduction in the numeric rating scale", 
            "safety_issue": "Yes", 
            "time_frame": "Eighteen months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084355"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Gyeongsang National University Hospital", 
            "investigator_full_name": "Jung Hun Kang", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Gyeongsang National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gyeongsang National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}